A Peek down the pipeline: Emerging drug delivery options for retinal disease

Thomas A Albini, Andrew A. Moshfeghi, Steven Yeh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The innovative approaches of these emerging ophthalmic devices and pharmaceuticals offer promising options for drug delivery that will likely strengthen the vitreoretinal specialist's armamentarium for patients with AMD, RVO, DME, and posterior uveitis in the future. Intravitreal implants with refillable reservoirs and suprachoroidal delivery via microcatheter delivery or hollow microneedles represent a few of the potential routes whereby sustainedrelease drug delivery may be achieved. In addition, the vehicles (Verisome technology, nanotechnology, others) by which medications are administered via intravitreal injections may also offer longer-term options to reduce the treatment burden of frequent injections and clinic visits. As evidenced by intravitreal implant options previously studied, the ophthalmic benefit-risk ratio, as well as the cost of these medications, will be critical to their implementation and widespread acceptance in the clinical setting. However, patients with retinal disease will likely have additional therapeutic options in the future as these promising drug delivery platforms move forward in development.

Original languageEnglish
Pages (from-to)70-77
Number of pages8
JournalRetina Today
VolumeJUL/AUG
StatePublished - Jan 1 2014

Fingerprint

Retinal Diseases
Pharmaceutical Preparations
Posterior Uveitis
Intravitreal Injections
Nanotechnology
Ambulatory Care
Odds Ratio
Technology
Costs and Cost Analysis
Equipment and Supplies
Injections
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A Peek down the pipeline : Emerging drug delivery options for retinal disease. / Albini, Thomas A; Moshfeghi, Andrew A.; Yeh, Steven.

In: Retina Today, Vol. JUL/AUG, 01.01.2014, p. 70-77.

Research output: Contribution to journalArticle

Albini, Thomas A ; Moshfeghi, Andrew A. ; Yeh, Steven. / A Peek down the pipeline : Emerging drug delivery options for retinal disease. In: Retina Today. 2014 ; Vol. JUL/AUG. pp. 70-77.
@article{c1183e49a33c490587ef987e77b33419,
title = "A Peek down the pipeline: Emerging drug delivery options for retinal disease",
abstract = "The innovative approaches of these emerging ophthalmic devices and pharmaceuticals offer promising options for drug delivery that will likely strengthen the vitreoretinal specialist's armamentarium for patients with AMD, RVO, DME, and posterior uveitis in the future. Intravitreal implants with refillable reservoirs and suprachoroidal delivery via microcatheter delivery or hollow microneedles represent a few of the potential routes whereby sustainedrelease drug delivery may be achieved. In addition, the vehicles (Verisome technology, nanotechnology, others) by which medications are administered via intravitreal injections may also offer longer-term options to reduce the treatment burden of frequent injections and clinic visits. As evidenced by intravitreal implant options previously studied, the ophthalmic benefit-risk ratio, as well as the cost of these medications, will be critical to their implementation and widespread acceptance in the clinical setting. However, patients with retinal disease will likely have additional therapeutic options in the future as these promising drug delivery platforms move forward in development.",
author = "Albini, {Thomas A} and Moshfeghi, {Andrew A.} and Steven Yeh",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "JUL/AUG",
pages = "70--77",
journal = "Retina Today",
issn = "1825-0572",
publisher = "Bryn Mawr Communications LLC",

}

TY - JOUR

T1 - A Peek down the pipeline

T2 - Emerging drug delivery options for retinal disease

AU - Albini, Thomas A

AU - Moshfeghi, Andrew A.

AU - Yeh, Steven

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The innovative approaches of these emerging ophthalmic devices and pharmaceuticals offer promising options for drug delivery that will likely strengthen the vitreoretinal specialist's armamentarium for patients with AMD, RVO, DME, and posterior uveitis in the future. Intravitreal implants with refillable reservoirs and suprachoroidal delivery via microcatheter delivery or hollow microneedles represent a few of the potential routes whereby sustainedrelease drug delivery may be achieved. In addition, the vehicles (Verisome technology, nanotechnology, others) by which medications are administered via intravitreal injections may also offer longer-term options to reduce the treatment burden of frequent injections and clinic visits. As evidenced by intravitreal implant options previously studied, the ophthalmic benefit-risk ratio, as well as the cost of these medications, will be critical to their implementation and widespread acceptance in the clinical setting. However, patients with retinal disease will likely have additional therapeutic options in the future as these promising drug delivery platforms move forward in development.

AB - The innovative approaches of these emerging ophthalmic devices and pharmaceuticals offer promising options for drug delivery that will likely strengthen the vitreoretinal specialist's armamentarium for patients with AMD, RVO, DME, and posterior uveitis in the future. Intravitreal implants with refillable reservoirs and suprachoroidal delivery via microcatheter delivery or hollow microneedles represent a few of the potential routes whereby sustainedrelease drug delivery may be achieved. In addition, the vehicles (Verisome technology, nanotechnology, others) by which medications are administered via intravitreal injections may also offer longer-term options to reduce the treatment burden of frequent injections and clinic visits. As evidenced by intravitreal implant options previously studied, the ophthalmic benefit-risk ratio, as well as the cost of these medications, will be critical to their implementation and widespread acceptance in the clinical setting. However, patients with retinal disease will likely have additional therapeutic options in the future as these promising drug delivery platforms move forward in development.

UR - http://www.scopus.com/inward/record.url?scp=84906084752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906084752&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84906084752

VL - JUL/AUG

SP - 70

EP - 77

JO - Retina Today

JF - Retina Today

SN - 1825-0572

ER -